BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come
Investor's Business DailyBioNTech stock lifted a fraction Monday after Covid vaccine sales dropped again in the first quarter, amid wide losses.
The post BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come appeared first on Investor's Business Daily.